Dr. Pasi Janne, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Dana-farber Cancer Institute

  Fellowship Hospital

• Brigham And Womens Hospital

  Residency Hospital, 1998

• Brigham And Womens Hospital

  Internship Hospital, 1997

• University Of Pennsylvania Perelman School Of Medicine

  Medical School, 1996

• Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors, 2018-08-27

• Management of acquired resistance to EGFR kinase inhibitors in advanced NSCLC, 2014-04-17

• Discovery of a Potent Dual ALK and EGFR T790M Inhibitor, 2017-05-03

• Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR mutant Lung Cancer, 2015-06-02

• Targeting MET Dysregulation in Cancer, 2020-06-12

• Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors, 2012-12-14

• A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer, 2022-04-15

• Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies forHER2mutant non small cell lung cancer, 2020-02-07

• Oncogenic switch and single-agent MET inhibitor sensitivity in a subset ofEGFR-mutant lung cancer, 2021-09-01

• MPS1 inhibition primes immunogenicity ofKRAS-LKB1mutant lung cancer, 2022-09-22

• Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903), 2020-12-29

• EGFRExon 19 Insertions: A New Family of SensitizingEGFRMutations in Lung Adenocarcinoma, 2011-12-21

• Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome, 2017-07-05

• Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer, 2020-04-20

• MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer, 2022-11-02

• Brief report: Clinical implications of variantALKFISH rearrangement patterns, 2015-07-30

• Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care, 2016-08-01

• ROS1 Immunohistochemistry for Detection ofROS1-Rearranged Lung Adenocarcinomas, 2013-06-07

• Impact of Epidermal Growth Factor Receptor andKRASMutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials, 2009-08-11

• Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization, 2013-09-24

• Efficacy of a cancer vaccine against ALK-rearranged lung tumors, 2015-09-29

• An Amino-indazole Scaffold with Spectrum Selective Kinase Inhibition of FLT3, PDGFRa and Kit, 2012-06-06

• Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer, 2023-08-15

• A Severe Photosensitivity Dermatitis Caused by Crizotinib, 2015-03-14

• A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG), 2014-08-21

• RB loss in resistantEGFRmutant lung adenocarcinomas that transform to small-cell lung cancer, 2015-03-11

• Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors, 2022-09-24

• CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer: Performance Characteristics of an Emerging Clinical Tool, 2010-10-30

• Single and dual targeting of mutant EGFR with an allosteric inhibitor, 2019-05-15

• Reactivation of ERK Signaling causes resistance to EGFR kinase inhibitors, 2012-09-07

• Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity, 2021-03-11

• IncreasedSOX2Gene Copy Number Is Associated withFGFR1andPIK3CAGene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease, 2014-04-15

• Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib, 2018-11-01

• Clinician Perspectives on Current Issues in Lung Cancer Drug Development, 2016-07-09

• Amplification ofEGFRT790M causes resistance to an irreversible EGFR inhibitor, 2010-02-01

• Primary Pulmonary NUT-Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterization, 2015-03-28

• EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors, 2015-05-06

• AcquiredMETD1228V mutation and resistance to MET inhibition in lung cancer, 2016-09-30

• A structural model of a Ras-Raf signalosome, 2021-10-08

• Chemotherapy and irradiation for locally advanced and metastatic pulmonary carcinoid tumors, 2014-08-27

• Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer, 2016-02-10

• New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy, 2011-06-28

• Rapamycin prevents the development and progression of mutant EGFR lung tumors with the acquired resistance mutation T790M, 2014-06-12

• Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors, 2011-01-25

• A Novel, Highly Sensitive Antibody Allows for the Routine Detection ofALK-rearranged Lung Adenocarcinomas by Standard Immunohistochemistry, 2010-02-23

• A Pooled Exploratory Analysis of the Effect of Tumor Size andKRASMutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy in Node Negative Non-Small Cell Lung Cancer, 2012-06-13

• Tumor Volume Decrease at 8 weeks is Associated with Longer Survival inEGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor, 2013-05-20

• Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer WithEGFRExon 20 Insertion Mutations From a Phase 1/2 Trial, 2021-02-25

• Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer, 2016-10-17

• Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab, 2011-09-07

• Clinical, pathological and biological features associated withBRAFmutations in non-small cell lung cancer, 2013-07-05

• EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry, 2011-06-03

• TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation, 2010-08-17

• Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM and ATR, 2013-02-22

• Mobocertinib (TAK-788) inEGFRExon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort, 2022-12-23

• Mutations in theDDR2kinase gene identify a novel therapeutic target in squamous cell lung cancer, 2011-04-03

• The quest to overcome resistance to EGFR-targeted therapies in cancer, 2013-11-07

• Natural history and molecular characteristics of lung cancers harboringEGFRexon 20 insertions, 2012-11-15

• Small Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver., 2018-01-26

• Monitoring Cancer through the blood, 2014-08-07

• Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab inEGFRWild-type Cancers, 2008-11-01

• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, 2012-09-14

• Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance, 2021-11-17

• Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone, 2015-03-15

• Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK), 2018-04-24

• Loss ofLkb1andPtenLeads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression, 2014-05-01

• Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer, 2019-11-12

• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, 2016-02-17

• The landscape of somatic copy-number alteration across human cancers, 2010-02-18

• A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer, 2017-03-28

• Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway, 2020-01-13

• Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: implications for targeted therapy development, 2016-08-15

• Phase I Dose-escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors, 2011-01-10

• Discovery of selective irreversible inhibitors for EGFR-T790M, 2010-12-10

• A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response, 2012-03-18

• Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients, 2015-10-12

• A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing, 2018-09-21

• Pharmacological Targeting of the Pseudokinase Her3, 2014-10-19

• Amplification ofCRKLinduces transformation and EGFR inhibitor resistance in human non small cell lung cancers, 2011-10-17

• Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET, 2012-05-02

• New Strategies for Treatment of ALK Rearranged Non-Small Cell Lung Cancers, 2011-10-18

• The introduction of systematic genomic testing for patients with non-small cell lung cancer, 2012-10-19

• EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, 2008-07-01

• Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor**, 2013-11-20

• Noninvasive detection of response and resistance inEGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA, 2014-01-15

• ERK inhibitor LY3214996-based treatment strategies forRAS-driven lung cancer, 2021-02-03

• The KRASG12CInhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients, 2019-10-28

• The neuroblastoma associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK translocated cancers, 2010-10-28

• Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations, 2022-07-06

• 30 years of HER3: From basic biology to therapeutic interventions, 2021-02-19

• Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors, 2017-03-31

• Identification of existing drugs that effectively targetNTRK1- andROS1-rearrangements in lung cancer, 2016-07-01

• FGFR2Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma, 2021-04-29

• Brief report:EGFRL858M/L861Q cis mutations confer selective sensitivity to afatinib, 2017-01-11

• Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors, 2020-03-25

• Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboringMETexon 14 mutations: a retrospective analysis, 2019-05-11

• Lung cancer diagnosed in the young is associated with enrichment for targetable genomic alterations and poor prognosis, 2016-03-01

• Discovery of inhibitors that overcome the G1202R ALK Resistance Mutation, 2015-11-25

• Unraveling the clinicopathological features driving the emergence ofESR1mutations in metastatic breast cancer, 2018-08-02

• Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations, 2020-07-09

• A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307, 2013-05-24

• AcquiredEGFRC797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboringEGFRT790M, 2015-05-04

• Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors, 2016-05-25

• Intratumoral heterogeneity inEGFRmutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition, 2015-08-17

• Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy, 2020-11-17

• Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, 2013-09-27

• Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer, 2011-07-20

• Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study, 2016-02-11

• Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations A. Oginoet al., 2020-11-25

• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, 2009-12-24

• Detection of T790M, the acquired resistanceEGFRmutation, by tumor biopsy versus noninvasive blood-based analyses, 2015-10-07

• EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd, 2021-09-21

• Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib, 2020-10-20

• Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC, 2022-04-01

• Power in Numbers: Meta-analysis to Identify Inhibitor-Sensitive Tumor Genotypes, 2013-02-12

• Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients, 2016-12-20

• RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0, 2013-07-22

• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants, 2005-10-04

• Activation of tumor-cell STING primes NK-cell therapy, 2022-08-03

• Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade, 2022-06-16

• Concurrent TP53 mutations facilitate resistance evolution in EGFR mutant lung adenocarcinoma, 2022-03-21

• Pre-existence and clonal selection ofMETamplification inEGFRmutant NSCLC, 2010-01-19

• Identification of newALKandRETgene fusions from colorectal and lung cancer biopsies, 2012-02-12

• A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors, 2011-07-26

• CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC., 2019-07-04

• Lung Adenocarcinoma withEGFRAmplification has Distinct Clinicopathologic and Molecular Features in Never-Smokers, 2009-10-13

• Amplification of wild typeKRASimparts resistance to crizotinib inMETexon 14 mutant non-small cell lung cancer, 2018-08-02

• Trastuzumab Deruxtecan inHER2-Mutant Non-Small-Cell Lung Cancer, 2021-09-18

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors, 2022-05-09

• Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer, 2023-04-06

• Development of small molecules targeting the pseudokinase Her3, 2015-05-11

• A dominant-negative effect drives selection ofTP53missense mutations in myeloid malignancies, 2019-08-09

• Volumetric tumor growth in advanced NSCLC patients withEGFRmutations during EGFR-TKI therapy: Developing criteria to continue therapy beyond RECIST progression, 2013-08-06

• Co-clinical trials demonstrate superiority of crizotinib to chemotherapy inALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance, 2013-12-10

• RB Loss in ResistantEGFRMutant Lung Adenocarcinomas that Transform to Small Cell Lung Cancer, 2015-03-11

• Allosteric inhibition of drug resistant forms ofEGFRL858R mutant NSCLC, 2022-04-14

• The Biology and Treatment ofEML4-ALKNon-Small Cell Lung Cancer, 2010-04-24

• SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer, 2018-11-16

• Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy, 2015-02-26

• STK11/LKB1Mutations and PD-1 Inhibitor Resistance inKRAS-Mutant Lung Adenocarcinoma, 2018-05-17

• Five-year survival inEGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs, 2015-12-25

• Delay of treatment change following objective progression on first-line erlotinib inEGFR-mutant lung cancer, 2015-04-15

• Clinical and molecular characteristics ofNF1mutant lung cancer, 2016-02-09